MedTrace Logo

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

NCT05643677 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2022-12-09

No results posted yet for this study

Summary

This study explores the efficacy and safety of fruquintinib combined with irinotecan in the second-line treatment of patients with advanced gastric cancer, aiming to bring more second-line treatment options for patients with advanced gastric cancer.

Conditions

Interventions

DRUG

Fruquintinib

4 mg PO, QD (3 weeks on, 1 week off)

DRUG

Irinotecan

participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Principal Investigators

  • Xi Shi · First Affiliated Hospital of Fujian Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2024-11-30
Completion
2025-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05643677 on ClinicalTrials.gov